American College of Chest Physicians (CHEST) advocates for broader coverage of supplemental oxygen use
31 August 2021
LONDON, U.K. AND PLANO, TX, U.S. (31 August 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, welcomes the recent statement issued by the American College of Chest Physicians (CHEST) on the rationale for home use of oxygen coverage beyond cluser headacheds.
In response to the US Centers for Medicare & Medicaid Services (CMS) proposed decision on the appropriate use of oxygen for cluster headaches and expanding coverage for the home use of oxygen, CHEST, a worldwide community of over 19,000 clinicians advancing patient care in chest medicine, submitted rationale to CMS to expand the home use of oxygen. The rationale was joined by several other major healthcare organizations including the American Association for Respiratory Care, American Lung Association, COPD Foundation and the American Thoracic Society.
A key rationale for expanding the ability of practitioner is to allow:
"… maximum flexibility of the treating practitioner to determine clinically appropriate oxygen use based on medical need, without the patient having to first try and fail other therapeutic alternatives, is an important change and one that can help improve overall patient care."
The entire rationale can be found on the CHEST website: https://www.chestnet.org/Newsroom/CHEST-News/2021/08/CHEST-advocates-for-broader-coverage-of-supplemental-oxygen-use
Robert Rauker, Belluscura CEO, commented: "This CHEST rationale, following on so closely from the CMS proposals, highlights the expanding demand for home Oxygen, and the increasing opportunity for Belluscura's novel oxygen concentrator technology. Shareholders will be kept fully updated on developments from CHEST and CMS."
For further information please contact:
Robert Rauker, Chief Executive Officer
via Walbrook PR
Anthony Dyer, Chief Financial Officer
SPARK Advisory Partners Limited (NOMAD)
Tel: +44 (0)20 3368 3550
Dowgate Capital Limited (Broker)
Tel: +44 (0)20 3903 7715
James Serjeant / Nicholas Chambers
Walbrook PR Ltd (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Sam Allen
Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
About RNS Reach announcements
RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.